Korean J Urol.  2009 Sep;50(9):831-835.

Recent Investigations of Urinary Nerve Growth Factor as a Biomarker for Overactive Bladder Syndrome

• Kuo HC

Abstract

PURPOSE
Overactive bladder (OAB) is a symptom syndrome and is usually diagnosed by subjective symptoms of urgency with or without urgency incontinence. However, because urgency symptoms are so subjective, it is difficult to objectively grade symptoms of urgency. Although urodynamic study can detect detrusor overactivity (DO) objectively, not all patients with OAB are found to have DO. Therefore, recent research interests have focused on urinary and image biomarkers in the assessment of OAB. MATERIALS AND METHODS: Investigating articles from the literature and recent published works were reviewed. RESULTS: The urinary nerve growth factor (NGF) level is found to increase in patients with OAB-wet, bladder outlet obstruction, mixed urinary incontinence, and urodynamic DO. NGF levels are correlated with OAB symptoms and return to normal after treatment. However, urinary NGF is not increased only in patients with OAB and DO. It also increases in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) and other lower urinary tract diseases such as urinary tract stones, bacterial infection, and urothelial tumor. Thirty percent of OAB patients have a low urinary NGF level. Nevertheless, antimuscarinic or botulinum toxin treatment can decrease the urinary NGF level, and changes in the NGF level are correlated with the urgency severity scale. CONCLUSIONS: It is therefore possible to use urinary NGF levels as a biomarker for assessment of therapeutic outcome in patients with OAB. Further research on combined multiple biomarkers to differentiate OAB and IC/PBS is necessary.

Keyword

Overactive urinary bladder; Nerve growth factor; Urodynamics

MeSH Terms

Bacterial Infections
Biomarkers
Botulinum Toxins
Humans
Nerve Growth Factor
Urinary Bladder
Urinary Bladder Neck Obstruction
Urinary Bladder, Overactive
Urinary Calculi
Urinary Incontinence
Urodynamics
Urologic Diseases
Botulinum Toxins
Nerve Growth Factor

Figure

• 

  Fig. 1 Urinary NGF/Cr levels in patients with bacterial cystitis at baseline (BL) and after treatment (Tx). NGF: nerve growth factor, Cr: creatinine, OAB: overactive bladder, UTI: urinary tract infection.

Reference

1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000. 6(11):Suppl. S580–S590.

2. Romanzi LJ, Groutz A, Heritz DM, Blaivas JG. Involuntary detrusor contractions: correlation of urodynamic data to clinical categories. Neurourol Urodyn. 2001. 20:249–257.

3. Lee KS, Lee YS. Overactive bladder. Korean J Urol. 2007. 48:1191–1208.

4. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006. 49:644–650.

5. Kim DY, Kim JW, Yang EK. Altered expressions of calcium-activated potassium channel and connexin in bladder mucosae of stress urinary incontinence ptients with overactive bladder symptoms. Korean J Urol. 2006. 47:722–728.

6. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006. 175:191–194.

7. Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol. 2000. 161:273–284.

8. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol. 1999. 57:583–606.

9. Vizzard MA. Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury. Prog Brain Res. 2006. 152:97–115.

10. Seki S, Sasaki K, Fraser MO, Igawa Y, Nishizawa O, Chancellor MB, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol. 2002. 168:2269–2274.

11. Seki S, Sasaki K, Igawa Y, Nishizawa O, Chancellor MB, De Groat WC, et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol. 2004. 171:478–482.

12. Weaver LC, Marsh DR, Gris D, Brown A, Dekaban GA. Autonomic dysreflexia after spinal cord injury: central mechanisms and strategies for prevention. Prog Brain Res. 2006. 152:245–263.

13. Okragly AJ, Niles AL, Saban R, Schmidt D, Hoffman RL, Warner TF, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol. 1999. 161:438–441.

14. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997. 79:572–577.

15. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007. 70:463–468.

16. Tuttle JB, Steers WD, Albo M, Nataluk E. Neural input regulates tissue NGF and growth of the adult urinary bladder. J Auton Nerv Syst. 1994. 49:147–158.

17. Dupont MC, Spitsberegen JM, Kim KB, Tuttle JB, Steers WD. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol. 2000. 166:1111–1118.

18. Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, Botchkareva NV, Paus R, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol. 1999. 155:1183–1193.

19. Lamb K, Gebhart GF, Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. J Pain. 2004. 5:150–156.

20. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006. 175:1773–1776.

21. Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn. 2008. 27:417–420.

22. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol. 2008. 179:2270–2274.

23. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology. 2008. 72:104–108.

24. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol. 2008. Epub ahead of print.

25. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 2008. 102:1440–1444.

26. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009. 103:1668–1672.

27. Liu HT, Liu AB, Chancellor MB, Kuo HC. Urinary nerve growth factor levels is correlated with severity of neurological impairment in patients with cerebrovascular accident. BJU Int. 2009. Epub ahead of print.

28. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009. Epub ahead of print.